Tarsus Pharmaceuticals, Inc. TARS Other Income (Expense)
Other Income (Expense) at other companies
Other financials
Where this comes from
Reported directly by Tarsus Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NonoperatingIncomeExpense.
The official record: Tarsus Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Tarsus Pharmaceuticals, Inc.'s other income (expense).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Tarsus Pharmaceuticals, Inc.'s other income (expense)?
- Tarsus Pharmaceuticals, Inc. (TARS) reported other income (expense) of $1.51M in Q1 2026.
- How has Tarsus Pharmaceuticals, Inc.'s other income (expense) changed year-over-year?
- Tarsus Pharmaceuticals, Inc.'s other income (expense) increased by 29.9% year-over-year, from $1.16M to $1.51M.
- What is the long-term trend for Tarsus Pharmaceuticals, Inc.'s other income (expense)?
- Over 4 years (2021 to 2025), Tarsus Pharmaceuticals, Inc.'s other income (expense) has grown at a 42.2% compound annual growth rate (CAGR), from -$1.62M to $6.61M.
- What does other income (expense) mean?
- Net total of all non-operating income and expenses not classified in specific line items — a catch-all for miscellaneous financial items.